Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Author(s):: Verschoor, Y.L.; Haar, J. van de; Berg, J.G. van den; Sandick, J.W. van; Kodach, L.L.; Dieren, J.M. van; Balduzzi, S.; Grootscholten, C.; Ijsselsteijn, M.E.; Veenhof, A.A.F.A.; Hartemink, K.J.; Vollebergh, M.A.; Jurdi, A.; Sharma, S.; Spickard, E.; Owers, E.C.; Bartels-Rutten, A.; Hartog, P. den; Miranda, N.F.C.C. de; Leerdam, M.E. van; Haanen, J.B.A.G.; Schumacher, T.N.; Voest, E.E.; Chalabi, M.

Published: 2024
Publication type: Article / Letter to editor

Date issued: 2024-03-06
Language: English
Publisher: Nature Research
Is part of: Nature Medicine
hdl: 1887/3764521
doi: 10.1038/s41591-024-02898-8
URL: https://www.nature.com/articles/s41591-024-02898-8